Advanced search
Publication Cover
International Journal of Nephrology and Renovascular Disease Volume 13, 2020 - Issue
Submit an article Journal homepage
197
Views
9
CrossRef citations to date
0
Altmetric
Original Research

Calciphylaxis: An Analysis of Concomitant Factors, Treatment Effectiveness and Prognosis in 30 Patients

Sarju Panchal1 Department of Internal Medicine, Hospital of University of Pennsylvania, Philadelphia, PA19146, USA
,
Kirstie Holtermann2 Department of Medicine, University of Missouri School of Medicine, Columbia, MO65212, USA
,
Namrita Trivedi1 Department of Internal Medicine, Hospital of University of Pennsylvania, Philadelphia, PA19146, USA
,
Hariharan Regunath3 Department of Medicine – Divisions of Pulmonary, Critical Care and Infectious Diseases, University of Missouri School of Medicine, Columbia, MO65212, USAORCID Iconhttps://orcid.org/0000-0003-4223-8765
ORCID Icon &
Preethi Yerram4 Department of Medicine – Division of Nephrology, University of Missouri School of Medicine, Columbia, MO65212, USACorrespondence[email protected]
Pages 65-71 | Published online: 05 Apr 2020

References

  • Nigwekar SU, Thadhani R, Brandenburg VM. Calciphylaxis. N Engl J Med. 2018;378(18):1704–1714. doi:10.1056/NEJMra150529229719190
  • Mccarthy JT, El-azhary RA, Patzelt MT, et al. Survival, risk factors, and effect of treatment in 101 patients with calciphylaxis. Mayo Clin Proc. 2016;91(10):1384–1394. doi:10.1016/j.mayocp.2016.06.02527712637
  • Kramann R, Bradenburg VM, Schurgers IJ, et al. Novel insights into osteogenesis and matrix remodeling association with calcific uremic arteriolopathy. Nephrol Dial Transplant. 2013;28:856–868. doi:10.1093/ndt/gfs46623223222
  • Mazhar AR, Johnson RJ, Gillen D, et al. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int. 2001;60(1):324–332. doi:10.1046/j.1523-1755.2001.00803.x11422768
  • Nigwekar SU, Brunelli SM, Meade D, Wang W, Hymes J, Lacson E. Sodium thiosulfate therapy for calcific uremic arteriolopathy. Clin J Am Soc Nephrol. 2013;8(7):1162–1170. doi:10.2215/CJN.0988091223520041
  • Bleyer AJ, Choi M, Igwemezie B, De la Torre E, White WL. A case control study of proximal calciphylaxis. Am J Kidney Dis. 1998;32(3):376–383. doi:10.1053/ajkd.1998.v32.pm97401529740152
  • Zhang Y, Corapi KM, Luongo M, Thadhani R, Nigwekar SU. Calciphylaxis in peritoneal dialysis patients: a single center cohort study. Int J Nephrol Renovasc Dis. 2016;9:235–241. doi:10.2147/IJNRD.S11570127698566
  • Angelis M, Wong LL, Myers SA, Wong LM. Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery. 1997;122(6):1083–1089. doi:10.1016/S0039-6060(97)90212-99426423
  • Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int. 2002;61(6):2210–2217. doi:10.1046/j.1523-1755.2002.00375.x12028462
  • Nigwekar SU, Bhan I, Turchin A, et al. Statin use and calcific uremic arteriolopathy: a matched case-control study. Am J Nephrol. 2013;37(4):325–332. doi:10.1159/00034880623548843
  • Hayashi M, Takamatsu I, Kanno Y, et al. A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant. 2012;27(4):1580–1584. doi:10.1093/ndt/gfr65822121234
  • Galloway PA, El-damanawi R, Bardsley V, et al. Vitamin K antagonists predispose to calciphylaxis in patients with end-stage renal disease. Nephron. 2015;129(3):197–201. doi:10.1159/00037144925720849
  • Amuluru L, High W, Hiatt KM, et al. Metal deposition in calcific uremic arteriolopathy. J Am Acad Dermatol. 2009;61(1):73–79. doi:10.1016/j.jaad.2009.01.04219406504
  • Farah M, Crawford RI, Levin A, Chan Yan C. Calciphylaxis in the current era: emerging ‘ironic’ features? Nephrol Dial Transplant. 2011;26(1):191–195. doi:10.1093/ndt/gfq40720627865
  • Nigwekar SU, Zhao S, Wenger J, et al. A nationally representative study of calcific uremic arteriolopathy risk factors. J Am Soc Nephrol. 2016;27(11):3421–3429. doi:10.1681/ASN.201509106527080977
  • Weenig RH, Sewell LD, Davis MD, Mccarthy JT, Pittelkow MR. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol. 2007;56(4):569–579. doi:10.1016/j.jaad.2006.08.06517141359
  • Brandenburg V, Sinha S, Torregrosa JV, et al. Phase 2 open label single arm repeat dose study to assess the effect of SNF472 on wound healing in uraemic calciphylaxis patients. J Am Soc Nephrol. 2017;28. doi:10.1681/ASN.2016080886

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.